Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients' Survival.
HDAC
immunohistochemistry
prognosis
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Sep 2021
23 Sep 2021
Historique:
received:
27
08
2021
revised:
12
09
2021
accepted:
20
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults, exerting high metastatic potential and poor prognosis. Histone deacetylases (HDACs) play a key role in carcinogenesis, and HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical settings. The aim of this study was to evaluate the clinical significance of HDAC-1, -2, -4, and -6 expression in UM. HDAC-1, -2, -4, and -6 expression was examined immunohistochemically in 75 UM tissue specimens and was correlated with tumors' clinicopathological characteristics, the presence of tumor-infiltrating lymphocytes (TILS), as well as with our patients' overall survival (OS). HDAC-2 was the most frequently expressed isoform (66%), whereas we confirmed in addition to the expected nuclear expression the presence of cytoplasmic expression of class I HDAC isoforms, namely HDAC-1 (33%) and HDAC-2 (9.5%). HDAC-4 and -6 expression was cytoplasmic. HDAC-1 nuclear expression was associated with increased tumor size ( These findings provide evidence for a potential role of HDACs and especially HDAC-2 in the biological mechanisms governing UM evolution and progression.
Sections du résumé
BACKGROUND
BACKGROUND
Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults, exerting high metastatic potential and poor prognosis. Histone deacetylases (HDACs) play a key role in carcinogenesis, and HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical settings. The aim of this study was to evaluate the clinical significance of HDAC-1, -2, -4, and -6 expression in UM.
METHODS
METHODS
HDAC-1, -2, -4, and -6 expression was examined immunohistochemically in 75 UM tissue specimens and was correlated with tumors' clinicopathological characteristics, the presence of tumor-infiltrating lymphocytes (TILS), as well as with our patients' overall survival (OS).
RESULTS
RESULTS
HDAC-2 was the most frequently expressed isoform (66%), whereas we confirmed in addition to the expected nuclear expression the presence of cytoplasmic expression of class I HDAC isoforms, namely HDAC-1 (33%) and HDAC-2 (9.5%). HDAC-4 and -6 expression was cytoplasmic. HDAC-1 nuclear expression was associated with increased tumor size (
CONCLUSIONS
CONCLUSIONS
These findings provide evidence for a potential role of HDACs and especially HDAC-2 in the biological mechanisms governing UM evolution and progression.
Identifiants
pubmed: 34638249
pii: cancers13194763
doi: 10.3390/cancers13194763
pmc: PMC8507547
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2020 Dec 09;12(12):
pubmed: 33316946
Mod Pathol. 2012 Feb;25(2):222-30
pubmed: 22037263
BMC Gastroenterol. 2015 Oct 26;15:148
pubmed: 26502922
Ann Surg Oncol. 2010 Dec;17(12):3336-43
pubmed: 20585871
Am J Ophthalmol. 1983 Oct;96(4):502-9
pubmed: 6624832
Diagnostics (Basel). 2021 Mar 14;11(3):
pubmed: 33799478
Anticancer Res. 2018 Jul;38(7):3817-3824
pubmed: 29970501
Curr Med Chem Anticancer Agents. 2002 Jul;2(4):477-84
pubmed: 12678732
J Breast Cancer. 2014 Dec;17(4):323-31
pubmed: 25548579
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Cells. 2021 Jan 31;10(2):
pubmed: 33572586
Clin Exp Metastasis. 2008;25(2):183-9
pubmed: 18058245
Adv Cancer Res. 2018;138:183-211
pubmed: 29551127
J Exp Clin Cancer Res. 2020 Dec 2;39(1):270
pubmed: 33267897
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
Cancers (Basel). 2021 Aug 18;13(16):
pubmed: 34439300
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Cancer Lett. 2009 Aug 8;280(2):168-76
pubmed: 19103471
Biochem J. 2003 Mar 15;370(Pt 3):737-49
pubmed: 12429021
Annu Rev Biochem. 2001;70:81-120
pubmed: 11395403
J Biol Chem. 2003 Nov 21;278(47):46541-8
pubmed: 12972430
Annu Rev Biochem. 2004;73:417-35
pubmed: 15189148
Expert Opin Investig Drugs. 2021 May;30(5):555-569
pubmed: 33650931
Life (Basel). 2020 Sep 30;10(10):
pubmed: 33007931
Cancers (Basel). 2021 Jul 30;13(15):
pubmed: 34359736
Tumour Biol. 2014 Jan;35(1):61-71
pubmed: 23873102
Curr Opin Pharmacol. 2003 Aug;3(4):344-51
pubmed: 12901942
J Transl Med. 2016 Jan 08;14:7
pubmed: 26747087
Indian J Ophthalmol. 2015 Feb;63(2):93-102
pubmed: 25827538
J Virol. 2001 Oct;75(20):9571-8
pubmed: 11559788
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441281
Cell Res. 2007 Mar;17(3):195-211
pubmed: 17325692
Genes Chromosomes Cancer. 1997 May;19(1):22-8
pubmed: 9135991
Ocul Oncol Pathol. 2019 Apr;5(3):153-161
pubmed: 31049320
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-49
pubmed: 16261189
J Oral Pathol Med. 2011 Oct;40(9):706-14
pubmed: 21457345